Previous Close | 13.99 |
Open | 13.80 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 13.69 - 14.32 |
52 Week Range | 7.58 - 21.44 |
Volume | |
Avg. Volume | 45,587 |
Market Cap | 179.951M |
Beta (5Y Monthly) | 3.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.79 |
Earnings Date | Oct 17, 2024 - Oct 21, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 38.00 |
In the last year, multiple insiders have substantially increased their holdings of Greenwich LifeSciences, Inc...
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update of the expansion of clinical sites into Spain. As previously announced, the Company has partnered with GEICAM, the largest academic breast cancer research network in Spa
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, accordin